Company intelligence / Profile preview

Henogen

Ownership: Private
Employees: ~400
Development stage: Other

Overview

Henogen is a leading European contract manufacturer specializing in viral vectors for gene therapies and vaccines. It was acquired by Thermo Fisher Scientific in January 2021 for approximately $875 million. The company operates two advanced facilities in Belgium with over 7,000 m² of clinical and commercial capacity and about 400 employees. Its expertise spans multiple classes of viral vectors used by global biopharma clients to develop advanced therapeutics, including COVID-19 vaccines.

Therapeutic areas: Infectious Diseases
Modalities: Viral vectorBiologic
Industry: Contract Manufacturing Organization

Partnerships

Previously partnered with AstraZeneca to support large-scale adenovirus vector production for the company's COVID-19 vaccine candidate prior to acquisition by Thermo Fisher.Other partnerships are typically confidential due to CDMO business model.

Beyond the preview

Go deeper on Henogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Henogen.